Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
First Advantage Co. stock logo
FA
First Advantage
$15.88
+0.7%
$13.59
$8.82
$19.01
$2.71B1.21.11 million shs646,580 shs
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
$10.90
-3.6%
$8.70
$4.72
$13.74
$1.42B1.821.31 million shs1.05 million shs
5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
First Advantage Co. stock logo
FA
First Advantage
+0.70%-0.75%+23.46%+31.67%-12.75%
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
-3.63%+3.61%+22.61%+21.65%+47.70%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
First Advantage Co. stock logo
FA
First Advantage
$15.88
+0.7%
$13.59
$8.82
$19.01
$2.71B1.21.11 million shs646,580 shs
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
$10.90
-3.6%
$8.70
$4.72
$13.74
$1.42B1.821.31 million shs1.05 million shs
5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
First Advantage Co. stock logo
FA
First Advantage
+0.70%-0.75%+23.46%+31.67%-12.75%
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
-3.63%+3.61%+22.61%+21.65%+47.70%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
First Advantage Co. stock logo
FA
First Advantage
2.40
Hold$18.5016.50% Upside
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
2.42
Hold$13.8627.13% Upside

Current Analyst Ratings Breakdown

Latest ARC, FCCN, NEO, and FA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/21/2026
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
DowngradeSell (D-)Sell (E+)
5/11/2026
First Advantage Co. stock logo
FA
First Advantage
Boost Price TargetNeutral$15.00 ➝ $18.00
5/8/2026
First Advantage Co. stock logo
FA
First Advantage
Set Price Target$18.00
5/8/2026
First Advantage Co. stock logo
FA
First Advantage
Boost Price TargetOverweight$15.00 ➝ $20.00
5/8/2026
First Advantage Co. stock logo
FA
First Advantage
Boost Price TargetOverweight$15.00 ➝ $18.00
4/29/2026
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
UpgradeHoldBuy$11.00
4/29/2026
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
Boost Price TargetBuy$13.00 ➝ $14.00
4/29/2026
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
UpgradeMarket PerformOutperform$12.00 ➝ $25.00
3/27/2026
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
Reiterated RatingSell (D-)
3/16/2026
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
Reiterated RatingMarket Perform
3/16/2026
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
Reiterated RatingBuy
(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
First Advantage Co. stock logo
FA
First Advantage
$1.61B1.70$1.55 per share10.25$6.25 per share2.54
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
$727.33M1.95$0.34 per share32.53$6.47 per share1.68
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
First Advantage Co. stock logo
FA
First Advantage
$37.29M$0.04529.3318.68N/A0.65%13.16%7.33%N/A
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
-$108.03M-$0.77N/A363.33N/A-13.30%-2.80%-1.72%8/4/2026 (Estimated)

Latest ARC, FCCN, NEO, and FA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026N/A
First Advantage Co. stock logo
FA
First Advantage
$0.21$0.26+$0.05N/AN/AN/A
4/28/2026Q1 2026
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
$0.0058$0.01+$0.0042-$0.13$184.54 million$186.67 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
First Advantage Co. stock logo
FA
First Advantage
N/AN/AN/AN/AN/A
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
First Advantage Co. stock logo
FA
First Advantage
0.61
3.85
3.85
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
0.41
4.42
4.06

Institutional Ownership

CompanyInstitutional Ownership
First Advantage Co. stock logo
FA
First Advantage
94.91%
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
98.50%

Insider Ownership

CompanyInsider Ownership
First Advantage Co. stock logo
FA
First Advantage
4.40%
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
1.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
First Advantage Co. stock logo
FA
First Advantage
5,500171.54 million163.50 millionNot Optionable
NeoGenomics, Inc. stock logo
NEO
NeoGenomics
2,500130.21 million128.78 millionOptionable

Recent News About These Companies

NeoGenomics’s (NASDAQ:NEO) Q1 CY2026: Beats On Revenue
NeoGenomics Reports First Quarter 2026 Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
First Advantage stock logo

First Advantage NYSE:FA

$15.88 +0.11 (+0.70%)
Closing price 06/5/2026 04:00 PM Eastern
Extended Trading
$15.90 +0.02 (+0.13%)
As of 06/5/2026 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

First Advantage Corporation provides employment background screening, identity, and verification solutions worldwide. It offers pre-onboarding products and solutions, such as criminal background checks, drug/health screening, extended workforce screening, FBI channeling, identity checks and biometric fraud mitigation tools, education/work history verification, driver records and compliance, healthcare credentials, executive screening, and other screening products. The company also provides post-onboarding solutions, including criminal records monitoring, healthcare sanctions, motor vehicle records, social media screening, and global sanctions and licenses; and other products comprising fleet/vehicle compliance, hiring tax credits and incentives, resident/tenant screening, and investigative research. Its products and solutions are used by personnel in recruiting, human resources, risk, compliance, vendor management, safety, and/or security in global enterprises, mid-sized, and small companies. The company was formerly known as Fastball Intermediate, Inc. and changed its name to First Advantage Corporation in March 2021. First Advantage Corporation was founded in 2002 and is based in Atlanta, Georgia.

NeoGenomics stock logo

NeoGenomics NASDAQ:NEO

$10.90 -0.41 (-3.63%)
Closing price 06/5/2026 04:00 PM Eastern
Extended Trading
$10.90 +0.00 (+0.05%)
As of 06/5/2026 05:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.